A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.

Caroline Even,Amaury Daste,Esma Saada-Bouzid,Gautier Lefebvre,Jérôme Fayette,Sylvie Zanetta,Marie Christine Kaminsky,Didier Cupissol,A. Prevost,Elodie Vauleon,Alison Claire Johnson,Sébastien Salas,Frederic Rolland,Miruna Timar David,Isabelle Jallut,Jessy Delaye,Jean Bourhis,Joel Guigay,Matthieu Texier,Anne Auperin

A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.

2019

6032Background: In the randomized phase III Study CA209141, Nivolumab (N) demonstrated significant overall survival (OS) benefit with favorable safety profile for platinum refractory R/M SCCHN and ...

Keywords:

Cell
Refractory
Interim analysis
Carcinoma
Nivolumab
Oncology
Pathology
Medicine
Internal medicine
in patient
head neck
safety profile
basal cell
platinum resistance
head and neck

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations